<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856388</url>
  </required_header>
  <id_info>
    <org_study_id>I 118807</org_study_id>
    <secondary_id>NCI-2009-01508</secondary_id>
    <nct_id>NCT00856388</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders</brief_title>
  <official_title>A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well giving fludarabine phosphate and melphalan together&#xD;
      with total-body irradiation followed by donor stem cell transplant works in treating patients&#xD;
      with hematologic cancer or bone marrow failure disorders. Giving low doses of chemotherapy&#xD;
      and total-body irradiation before a donor peripheral blood stem cell transplant helps stop&#xD;
      the growth of cancer cells or abnormal cells. It may also stop the patient's immune system&#xD;
      from rejecting the donor's stem cells. The donated stem cells may replace the patient's&#xD;
      immune cells and help destroy any remaining cancer or abnormal cells (graft-versus-tumor&#xD;
      effect)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the transplant related mortality (TRM) of this reduced intensity&#xD;
      transplantation (RIT) combination in a patient population that is usually not eligible for a&#xD;
      full myeloablative allogeneic transplant.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate engraftment, safety, clinical response, evidence of graft-versus-malignancy&#xD;
      effect/graft-versus-host disease (GVHD) and overall outcomes of treatment with our RIT&#xD;
      regimen across a variety of hematological conditions.&#xD;
&#xD;
      OUTLINE: Patients receive fludarabine phosphate intravenously (IV) over 30 minutes on days -5&#xD;
      to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body&#xD;
      irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
&#xD;
      Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis&#xD;
      congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of&#xD;
      melphalan.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2009</start_date>
  <completion_date type="Actual">March 13, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 100 TRM</measure>
    <time_frame>First 100 days</time_frame>
    <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to ANC Engraftment</measure>
    <time_frame>Days 30</time_frame>
    <description>Median Time to ANC Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Platelet Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>Median Time to Platelet Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Donor Chimerism - Blood</measure>
    <time_frame>Day 30</time_frame>
    <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Donor Chimerism - Blood</measure>
    <time_frame>Day 100</time_frame>
    <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GVHD Grade III-IV</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Acute GVHD grade III-IV&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 yr Extenstive Chronic GVHD</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>1 yr Extensive Chronic GVHD&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 yr Overall Survival</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Neutrophilic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage III Small Lymphocytic Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo total-body irradiation</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic stem cell transplantation</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Reduced intensity allogeneic stem cell transplant)</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>ATGAM</other_name>
    <other_name>lymphocyte immune globulin</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a histology documented hematologic malignancy or marrow disorder&#xD;
&#xD;
          -  Bone marrow failure disorders and other non-malignant hematologic or immunologic&#xD;
             disorders:&#xD;
&#xD;
               -  Acquired bone marrow failure disorders include aplastic anemia, paroxysmal&#xD;
                  nocturnal hemoglobinuria (PNH):&#xD;
&#xD;
                    -  Primary allogeneic hematopoietic stem cell transplantation (HSCT) is&#xD;
                       appropriate for selected patients with severe aplastic anemia; however,&#xD;
                       patients with aplastic anemia must have failed at least one cycle of&#xD;
                       standard immunosuppressive therapy with calcineurin inhibitor plus&#xD;
                       anti-thymocyte globulin (ATG) if a fully-matched donor is not available&#xD;
&#xD;
                    -  Patients with PNH must have a history of thrombosis related to PNH&#xD;
&#xD;
               -  Hereditary bone marrow failure disorders include Fanconi anemia or related&#xD;
                  chromosomal breakage syndrome dyskeratosis congenita, Diamond-Blackfan anemia,&#xD;
                  Shwachman-Diamond syndrome, Kostmann syndrome, congenital amegakaryocytic&#xD;
                  thrombocytopenia:&#xD;
&#xD;
                    -  Fanconi anemia or related chromosomal breakage syndrome: positive chromosome&#xD;
                       breakage analysis using diepoxybutane (DEB) or mitomycin C if applicable&#xD;
&#xD;
                    -  Dyskeratosis: diagnosis is supported by using either telomerase reverse&#xD;
                       transcriptase (TERC) gene mutation in autosomal dominant Dyskeratosis&#xD;
                       Congenita or Xlinked DKC1 gene mutation&#xD;
&#xD;
               -  Other non-malignant hematologic or immunologic disorders that require&#xD;
                  transplantation&#xD;
&#xD;
                    -  Quantitative or qualitative congenital platelet disorders (including but not&#xD;
                       limited to congenital amegakaryocytopenia, absent-radii syndrome,&#xD;
                       Glanzmann's thrombasthenia)&#xD;
&#xD;
                    -  Quantitative or qualitative congenital neutrophil disorders (including but&#xD;
                       not limited to chronic granulomatous disease, congenital neutropenia)&#xD;
&#xD;
                    -  Congenital primary immunodeficiencies (including but not limited to Severe&#xD;
                       Combined Immunodeficiency Syndrome, Wiskott-Aldrick syndrome, CD40 ligand&#xD;
                       deficiency, T-cell deficiencies)&#xD;
&#xD;
          -  Acute leukemias:&#xD;
&#xD;
               -  Subjects must be ineligible for conventional myeloablative transplantation;&#xD;
&#xD;
               -  Resistant or recurrent disease after at least one standard combination&#xD;
                  chemotherapy regime or first remission patients at high risk of relapse OR First&#xD;
                  remission patients at high risk of relapse:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)- antecedent myelodysplastic syndrome, secondary AML,&#xD;
                  high risk cytogenetic abnormalities or normal cytogenetics with high-risk&#xD;
                  molecular features (e.g. Flt3-ITD mutation, mixed-lineage leukemia [MLL],&#xD;
                  wildtype NPM1);&#xD;
&#xD;
               -  Acute lymphocytic leukemia (ALL)- high or standard risk ALL&#xD;
&#xD;
          -  Chronic Myeloid Leukemia (CML):&#xD;
&#xD;
               -  Chronic phase (intolerant or unresponsive to imatinib and/or other tyrosine&#xD;
                  kinase inhibitors), second chronic phase or accelerated phase who are ineligible&#xD;
                  for conventional myeloablative transplantation&#xD;
&#xD;
          -  Myeloproliferative and myelodysplastic syndromes (MDS):&#xD;
&#xD;
               -  Myelofibrosis (with/without splenectomy) with intermediate to high risk features&#xD;
&#xD;
               -  Advanced polycythemia vera not responding to standard therapy&#xD;
&#xD;
               -  MDS with an international prostate symptom score (IPSS) score of Int-2 or higher&#xD;
&#xD;
               -  MDS with lower IPSS scores Int-1 or less with severe clinical features such as&#xD;
                  severe neutropenia or thrombocytopenia or high risk chromosome abnormalities such&#xD;
                  as monosomy 7&#xD;
&#xD;
               -  Secondary massively parallel signature sequencing (MPSS) with any IPSS scores&#xD;
&#xD;
               -  Chronic myelomoncytic leukemia&#xD;
&#xD;
          -  Lymphoproliferative disease:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL)&#xD;
                  (recurrent or persistent) fludarabine refractory or with less than 6 months&#xD;
                  duration of complete response (CR) between courses of conventional therapy&#xD;
&#xD;
               -  Multiple myeloma, progressive disease after autologous stem cell transplant or as&#xD;
                  planned tandem (allogeneic transplant after prior autologous stem cell&#xD;
                  transplant)&#xD;
&#xD;
               -  Waldenstroms macroglobulinemia (failed one standard regimen)&#xD;
&#xD;
               -  High grade NHL and diffuse large B-cell lymphoma (DLBCL)&#xD;
&#xD;
               -  Not eligible for conventional myeloablative HSCT OR failed autologous HSCT&#xD;
&#xD;
               -  First remission lymphoblastic lymphoma, or small, non-cleaved cell lymphoma or&#xD;
                  mantle cell lymphoma&#xD;
&#xD;
          -  Hodgkin disease:&#xD;
&#xD;
               -  Relapsed or refractory after front-line therapy&#xD;
&#xD;
               -  Failed or were not eligible for autologous transplantation&#xD;
&#xD;
          -  Failed prior autotransplant&#xD;
&#xD;
          -  Age &gt;= 3 and =&lt; 75 years for blood and bone marrow transplants and age &gt;= 3, &lt; 60 for&#xD;
             cord blood transplants&#xD;
&#xD;
          -  No serious uncontrolled psychiatric illness&#xD;
&#xD;
          -  No concomitant active malignancy other than non-melanoma skin cancer&#xD;
&#xD;
          -  Non-pregnant and non-nursing women (women or men with reproductive potential should&#xD;
             agree to use an effective means of birth control)&#xD;
&#xD;
          -  Patients may have received prior autologous bone marrow transplant (BMT) or prior&#xD;
             myeloablative allogeneic BMT (at least 60 days have elapsed)&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy, radiation treatment and/or surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  DONOR: Permissible HLA matching: Related donors- single antigen mismatch at HLA A, B&#xD;
             or DRB 1; unrelated donors- a single antigen mismatch at HLA A, B, or C, +/-&#xD;
             additional single allele level mismatch at A, B, C or DRB1; cord blood &gt;= 4 out of 6&#xD;
             antigen match at HLA A, B, DRB1)&#xD;
&#xD;
          -  DONOR: Compatibility at the four most informative HLA loci: A, B, C and DRB1 are&#xD;
             important for reducing the risk of GVHD and successful transplant outcomes; the A, B,&#xD;
             C and DRB1 loci comprise 8 possible alleles (a haplotype being inherited from each&#xD;
             parent); one additional locus, HLA-DQ, is also typed to ascertain haplotypes and&#xD;
             assist in the search for a compatible donor; however mismatching at DQ has not been&#xD;
             shown to be associated with adverse outcomes; high resolution molecular typing (at the&#xD;
             allele level) is now the standard of care for unrelated donor searches and allows&#xD;
             greater refinement of the search strategy&#xD;
&#xD;
          -  DONOR: Matched related donor: a single antigen mismatch at A, B, or the DR transplant&#xD;
             from a family member is associated with a higher risk of GVHD but similar overall&#xD;
             survival when compared to full identity at these 3 regions; related donor/recipient&#xD;
             pairs must be matched at 5 of 6 HLA antigens (A, B, DRBl)&#xD;
&#xD;
          -  DONOR: Unrelated donor: when evaluating patients for unrelated donor transplant, a&#xD;
             higher degree of matching is preferred due to minimize the risk of GVHD; the A, B, C,&#xD;
             DRB1 and DQ loci, comprising 10 possible alleles, will be typed routinely for all&#xD;
             unrelated transplants; given the higher risk of TRM in mismatched transplants, RIT is&#xD;
             often the best way to mitigate the risk; evolving data from the National Marrow Donor&#xD;
             Program now makes it possible to estimate the risks of donor-recipient HLA mismatch at&#xD;
             the allele or antigen level; the higher risk from HLA-mismatching must be carefully&#xD;
             assessed with respect to the clinical urgency and the patient's risk by the transplant&#xD;
             physician; antigen level mismatches at DQ are inconsequential to transplant outcomes&#xD;
             and are ignored with respect to donor selection for the purposes of this protocol,&#xD;
             with matching requirements confined to the 8 loci involving HLA A, B, C and DRB1; for&#xD;
             the purpose of this protocol, a single antigen mismatch at HLA A, B, or C, with or&#xD;
             without additional single allele level mismatch may participate in this protocol for&#xD;
             voluntary unrelated donors (blood or marrow); patients must be at least antigen-level&#xD;
             matched at DRB1&#xD;
&#xD;
          -  DONOR: If a patient has no suitable family donor matched for 5 of 6 HLA antigens (A,&#xD;
             B, DRB1) and no suitable unrelated donor is identified or for reasons of urgency, the&#xD;
             patient can be considered a candidate for cord blood transplant, provided a cord blood&#xD;
             donor is identified with a &gt;= 4 out of 6 antigen match at HLA A, B, DRB1 antigens; the&#xD;
             cord blood product must provide a minimum of 2 x 10^7 nucleated cells/kg, test&#xD;
             negative for HIV and Hepatitis A, Band C, and sterility assays have no growth; the&#xD;
             cord blood products are located through the National Marrow Donor Program, the&#xD;
             American Registry, or the Bone Marrow Donor Worldwide or other established registries,&#xD;
             and may be stored in the N.Y Placental Cord Blood Bank, the St. Louis Cord Blood Bank,&#xD;
             or any of the established, registered International blood and marrow banks&#xD;
&#xD;
          -  DONOR: Donor must be healthy and have nonreactive test results for all infectious&#xD;
             disease assays as required by state and federal regulations; donors who screen&#xD;
             seropositive for hepatitis and/or syphilis must be cleared by infectious disease&#xD;
             consultation&#xD;
&#xD;
          -  DONOR: The donor must have no uncontrolled cardiopulmonary, renal, endocrine, hepatic&#xD;
             or psychiatric disease to render donation unsafe&#xD;
&#xD;
          -  DONOR: The donor must be able to give informed consent for peripheral blood stem cell&#xD;
             collection or bone marrow collection&#xD;
&#xD;
          -  DONOR: Syngeneic donors are not eligible&#xD;
&#xD;
          -  DONOR: Donors who have poor peripheral venous access, may require central venous line&#xD;
             placement for stem cell apheresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)&#xD;
&#xD;
          -  Karnofsky (adult) or Lansky (for =&lt; 16 years) performance status =&lt; 50%&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLCO) less than 40% predicted,&#xD;
             corrected for hemoglobin (Hb) and/or alveolar ventilation&#xD;
&#xD;
          -  Cardiac: left ventricular ejection fraction less than 40%&#xD;
&#xD;
          -  Bilirubin &gt;= 3 x upper limit of normal&#xD;
&#xD;
          -  Liver alkaline phosphatase &gt;= 3 x upper limit of normal&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvate transaminase&#xD;
             (SGPT) &gt;= 3 x upper limit of normal&#xD;
&#xD;
          -  Child's class B and C liver failure&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 40 cc/min by the modified Cockcroft-Gault formula&#xD;
             for adults or the Schwartz formula for pediatrics&#xD;
&#xD;
          -  Patients who have received maximally allowed doses (given in 2 Gy fractions, or&#xD;
             equivalent) of previous radiation therapy to various organs as follows:&#xD;
&#xD;
               -  Mediastinum 40 Gy&#xD;
&#xD;
               -  Heart (any volume) 36 Gy&#xD;
&#xD;
               -  Whole lungs 12 Gy&#xD;
&#xD;
               -  Small bowel (any volume) 46 Gy&#xD;
&#xD;
               -  Kidneys 12 Gy&#xD;
&#xD;
               -  Whole liver 20 Gy&#xD;
&#xD;
               -  Spinal cord (any volume) 36 Gy&#xD;
&#xD;
               -  Whole brain 30 Gy Enrollment of patients who previously receive higher than&#xD;
                  allowed dose of radiation to a small volume of lungs, liver, and brain will be&#xD;
                  determine by the discretion of the radiation oncologist on the study&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or&#xD;
             other condition which, in the opinion of treating physician, would make this protocol&#xD;
             unreasonably hazardous for the patient&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Patients who in the opinion of the treating physician are unlikely to comply with the&#xD;
             restrictions of allogeneic stem cell transplantation based on formal psychosocial&#xD;
             screening&#xD;
&#xD;
          -  Females of childbearing potential with a positive pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2016</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Leukemia, Neutrophilic, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day 100 TRM</title>
        <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
        <time_frame>First 100 days</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 100 TRM</title>
          <description>Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" lower_limit="3.08" upper_limit="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to ANC Engraftment</title>
        <description>Median Time to ANC Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Days 30</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to ANC Engraftment</title>
          <description>Median Time to ANC Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Platelet Engraftment</title>
        <description>Median Time to Platelet Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Day 100</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Platelet Engraftment</title>
          <description>Median Time to Platelet Engraftment&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="0" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Donor Chimerism - Blood</title>
        <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
        <time_frame>Day 30</time_frame>
        <population>All treated and eligible patients, who were able to complete testing</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Donor Chimerism - Blood</title>
          <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
          <population>All treated and eligible patients, who were able to complete testing</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Complete Donor Chimerism - Blood</title>
        <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
        <time_frame>Day 100</time_frame>
        <population>All treated and eligible patients, who were able to complete testing</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Donor Chimerism - Blood</title>
          <description>Rate of Complete Donor Chimerism - Blood&#xD;
Summarized using standard descriptive statistics.</description>
          <population>All treated and eligible patients, who were able to complete testing</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GVHD Grade III-IV</title>
        <description>Acute GVHD grade III-IV&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Up to day 100</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GVHD Grade III-IV</title>
          <description>Acute GVHD grade III-IV&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="16" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 yr Extenstive Chronic GVHD</title>
        <description>1 yr Extensive Chronic GVHD&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
        <time_frame>Up to 4.5 years</time_frame>
        <population>All treated and eligible who survived to day 100 and were eligible to get chronic GVHD</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.</description>
          </group>
        </group_list>
        <measure>
          <title>1 yr Extenstive Chronic GVHD</title>
          <description>1 yr Extensive Chronic GVHD&#xD;
Summarized using standard descriptive statistics along with corresponding 95% confidence intervals.</description>
          <population>All treated and eligible who survived to day 100 and were eligible to get chronic GVHD</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="45" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3 yr Overall Survival</title>
        <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 4.5 years</time_frame>
        <population>All treated and eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
            <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.&#xD;
fludarabine phosphate: Given IV&#xD;
melphalan: Given IV&#xD;
total-body irradiation: Undergo total-body irradiation&#xD;
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation&#xD;
anti-thymocyte globulin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>3 yr Overall Survival</title>
          <description>3 yr Overall Survival estimated using the Kaplan-Meier method.</description>
          <population>All treated and eligible patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="33.0" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)</title>
          <description>Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.&#xD;
Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.&#xD;
fludarabine phosphate: Given IV&#xD;
melphalan: Given IV&#xD;
total-body irradiation: Undergo total-body irradiation&#xD;
allogeneic hematopoietic stem cell transplantation: Undergo allogeneic stem cell transplantation&#xD;
anti-thymocyte globulin: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

